Home | By sponsor


Trials shown by sponsor

Public titlesort icon Date of Registration State
Effect and Safety of ior® EPOCIM in patients with Non-Hodking Lymphoma treated with anthracyclines. 2010-06-11 Registered
Effectiveness and safety of ior EPOCIM in anemia in premature infant. 2009-10-22 Registered
Effectiveness and Safety of use ior LeukoCIM as prophylaxis and treatment of Neutropenia in patients with HIV / AIDS. 2009-08-20 Registered
Effectiveness and Safety of ior EPOCIM in patients with Chronic Renal Failure on dialysis methods. 2009-07-10 Registered
Effectiveness and safety of ior®EPOCIM in Chronic Kidney Disease patients in pre-dialysis. 2011-11-11 Registered
Effectiveness and Safety of Nimotuzumab for the treatment of patients with glioma tumors 2009-09-18 Registered
EPOCIM in benign prostatic hyperplasia. 2009-10-23 Registered
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia. 2009-07-03 Registered
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy. 2009-07-03 Registered
Impact of the Granulocytes Colony-Stimulating Factor (ior-LeukoCIM) in primary and secondary prophylaxis and post chemotherapy and/or radiotherapy neutropenia in oncohematological pediatric patients. 2009-07-24 Registered
ior EPOCIM ® in the management of anemia of the preterm infant.Phase IV. 2013-02-26 Registered
ior ®EPOCIM as a cardioprotective agent in the surgery of rheumatic valvular disease. 26/08/2013 Registered outdated
iorEPOCIM-Stroke-Phase I 2012-09-17 Registered outdated
NeuroEPO in healthy volunteers. 2013-06-10 Registered
NeuroEPO – Type 2 Spinocerebellar Ataxia Phase I-II 02/11/2014 Registered
NeuroEPO-Stroke. Phase I-II 11/09/2014 Registered
Nimotuzumab for the treatment of high grade of malignancy tumors 2013-02-01 Registered
Nimotuzumab in tumors of head and neck .Phase IV 2013-02-01 Registered
Nimotuzumab- Head and neck cancer 2009-10-22 Registered
Safety assessment of Granulocyte Colony Stimulating Factor:ior LeukoCIM in oncohematologic patients.Phase IV study. 2009-07-24 Registered